Vol. 20/No. 7 | Oncology Live®

April 05, 2019

This year we are celebrating the 20th anniversary of our flagship publication OncologyLive. To mark the occasion, we are asking oncology leaders to reflect on the tremendous progress made in cancer research and practice over the past 2 decades.

April 01, 2019

During an OncLive Peer Exchange®, a panel of CLL experts review findings from studies presented at the 2018 American Society of Hematology meeting in December: iLLUMINATE, Alliance A041202, and ECOG E1912.

April 01, 2019

Now that the FDA has carved out nonmetastatic, castration-resistant prostate cancer as a new disease state, the decision about whether to administer recently approved antiandrogen therapies in this setting hinges on the rate of increase in prostate-specific antigen levels and comorbidities.

March 31, 2019

Although CAR T-cell therapy has not yet proved effective against solid tumors, a novel CAR that targets mesothelin proteins expressed in pancreatic cancer is showing early signs of activity.

March 29, 2019

Although TMB is associated with responses to checkpoint inhibitor therapy, more research is needed to better understand how TMB interacts with other genomic correlates of the immune cycle before the biomarker can be incorporated into clinical practice.

March 29, 2019

Aberrations in fibroblast growth factor receptor (FGFR) signaling are an emerging focus for targeted therapy across multiple types of cancer, particularly urothelial carcinoma, gastric cancer, and intrahepatic cholangiocarcinoma.

March 29, 2019

Following a multiyear trend in which oncology practices merged with hospitals to achieve savings and improved care, it appeared as though the pendulum was going to swing the other way.

March 28, 2019

Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.

March 28, 2019

Considering the decades of clinical investigation involving cytotoxic therapy of malignant disease, it is remarkable— even disconcerting—just how little is understood about the optimal delivery of this critical cancer treatment strategy.